Scarica l'app Stockscreener
1.01
1.94%
-0.02
Tscan Therapeutics Inc Borsa (TCRX) Ultime notizie
TScan Therapeutics Consolidates Finance Leadership After Officer Resignation - TipRanks
TScan Therapeutics announces resignation of vice president of finance - Investing.com UK
TScan Therapeutics announces resignation of vice president of finance By Investing.com - Investing.com Australia
TScan Therapeutics (TCRX) CFO adds principal accounting officer role after VP finance resignation - stocktitan.net
TCRX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Strong analyst sentiment on TScan Therapeutics (TCRX) amid ongoing momentum in cell therapy space - MSN
Strong Analyst Sentiment on TScan Therapeutics (TCRX) Amid Ongoing Momentum in Cell Therapy Space - Yahoo Finance
Earnings Risk: Will TScan Therapeutics Inc stock benefit from M A2026 Price Targets & Weekly High Potential Stock Alerts - baoquankhu1.vn
Aug Catalysts: Will TScan Therapeutics Inc outperform its industry peersQuarterly Portfolio Summary & Safe Entry Trade Reports - baoquankhu1.vn
Retail Trends: What is the implied volatility of TScan Therapeutics Inc2026 Price Targets & Scalable Portfolio Growth Methods - baoquankhu1.vn
How does TScan Therapeutics Inc score in quality rankings2026 Buyback Activity & Low Risk High Win Rate Picks - baoquankhu1.vn
Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care - The Globe and Mail
Risk Check: Will TScan Therapeutics Inc outperform its industry peersMarket Sentiment Report & Real-Time Volume Spike Alerts - baoquankhu1.vn
Geopolitics Watch: Is TScan Therapeutics Inc. stock risky to hold now2026 Action & AI Powered Market Trend Analysis - baoquankhu1.vn
TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
TCRX SEC FilingsTscan Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
TCRXTscan Therapeutics, Inc. Latest Stock News & Market Updates - Stock Titan
TScan Therapeutics (NASDAQ:TCRX) Downgraded to Sell Rating by Wall Street Zen - MarketBeat
Analysts Offer Insights on Healthcare Companies: Upstream Bio, Inc. (UPB), TScan Therapeutics (TCRX) and Teladoc (TDOC) - The Globe and Mail
Analysts Are Bullish on These Healthcare Stocks: Aligos Therapeutics (ALGS), Demant (WILLF) - The Globe and Mail
TScan Therapeutics (NASDAQ:TCRX) Price Target Raised to $5.00 - Defense World
TCRX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
What are the risks of holding TScan Therapeutics Inc2025 Trade Ideas & Weekly Consistent Profit Watchlists - baoquankhu1.vn
Stop Loss: What is the next catalyst for TScan Therapeutics Inc2025 Market WrapUp & Weekly Return Optimization Alerts - baoquankhu1.vn
HC Wainwright Issues Positive Outlook for TCRX Earnings - MarketBeat
FY2030 Earnings Estimate for TCRX Issued By HC Wainwright - MarketBeat
Tscan Therapeutics earnings beat by $0.09, revenue topped estimates - Investing.com Canada
TCRX: Pivotal trial for relapse-preventing T-cell therapy launches in Q2, targeting major market expansion - TradingView
TScan Therapeutics (NASDAQ:TCRX) Releases Quarterly Earnings Results, Beats Estimates By $0.09 EPS - MarketBeat
TScan Therapeutics, Inc. (TCRX) Posts Fourth Quarter Loss, Falls Short of Revenue Expectations - Bitget
TScan Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
The latest financial data from biotechnology company Tscan Therapeutics, Inc. shows that its current cash and cash equivalents are sufficient to support the company's daily operations and R&D investment through the second half of 2027. - Bitget
TScan Therapeutics 10-K: $10.3M Collaboration Revenue, $(129.8)M Net Loss - TradingView
TScan Therapeutics (NASDAQ: TCRX) advances TSC-101 and reshapes pipeline - Stock Titan
TScan Therapeutics (NASDAQ: TCRX) details 2025 loss, growth and cash runway - Stock Titan
Earnings Breakdown: TScan Therapeutics Q4 - Benzinga
TScan Therapeutics Q4 net loss widens - TradingView
BRIEF-TScan Therapeutics Q4 Net Income USD -22.977 Million - TradingView
TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - GlobeNewswire
Needham Reaffirms Their Buy Rating on TScan Therapeutics (TCRX) - The Globe and Mail
TScan Therapeutics completes enrollment in cohort C of Phase 1 Alloha(TM) trial - marketscreener.com
TScan Therapeutics Completes Enrollment in Cohort C of - GlobeNewswire
TScan Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference - The Manila Times
TScan Therapeutics to Present at TD Cowen 46th Annual Health Care Conference on March 4, 2026 - Quiver Quantitative
TScan Therapeutics (TCRX) Projected to Post Quarterly Earnings on Wednesday - Defense World
Is TScan Therapeutics Inc. stock a good dividend stockWeekly Stock Report & Risk Controlled Daily Plans - mfd.ru
TScan Therapeutics (NASDAQ:TCRX) Trading Up 4.6%Here's What Happened - MarketBeat
TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Is TScan Therapeutics Inc. stock a value trap2025 Sector Review & Low Drawdown Trading Techniques - mfd.ru
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
What’s next for TScan Therapeutics Inc. stockQuarterly Market Review & Comprehensive Market Scan Insights - mfd.ru
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):